The cistrome refers to "the set of cis-acting targets of a trans-acting factor on a genome-wide scale, also known as the in vivo genome-wide location of [transcription factor binding-sites] or histone modifications". The term cistrome is a portmanteau of cistr (from cistron) + ome (from genome). The term cistrome was coined by investigators at the Dana-Farber Cancer Institute and Harvard Medical School.